Remus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Remus Pharmaceuticals has a total shareholder equity of ₹1.2B and total debt of ₹208.5M, which brings its debt-to-equity ratio to 17%. Its total assets and total liabilities are ₹2.2B and ₹985.4M respectively. Remus Pharmaceuticals's EBIT is ₹392.5M making its interest coverage ratio -33.3. It has cash and short-term investments of ₹459.9M.
Key information
17.0%
Debt to equity ratio
₹208.45m
Debt
| Interest coverage ratio | -33.3x |
| Cash | ₹459.93m |
| Equity | ₹1.23b |
| Total liabilities | ₹985.40m |
| Total assets | ₹2.21b |
Recent financial health updates
No updates
Recent updates
We Ran A Stock Scan For Earnings Growth And Remus Pharmaceuticals (NSE:REMUS) Passed With Ease
Sep 25
Remus Pharmaceuticals Limited's (NSE:REMUS) P/E Is Still On The Mark Following 28% Share Price Bounce
Aug 20Returns On Capital Signal Tricky Times Ahead For Remus Pharmaceuticals (NSE:REMUS)
Jun 27Concerns Surrounding Remus Pharmaceuticals' (NSE:REMUS) Performance
May 23Remus Pharmaceuticals Limited (NSE:REMUS) Looks Just Right With A 29% Price Jump
May 21Financial Position Analysis
Short Term Liabilities: REMUS's short term assets (₹1.7B) exceed its short term liabilities (₹943.5M).
Long Term Liabilities: REMUS's short term assets (₹1.7B) exceed its long term liabilities (₹41.9M).
Debt to Equity History and Analysis
Debt Level: REMUS has more cash than its total debt.
Reducing Debt: Insufficient data to determine if REMUS's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: REMUS's debt is not well covered by operating cash flow (17.3%).
Interest Coverage: REMUS earns more interest than it pays, so coverage of interest payments is not a concern.